NXL
HEALTHCARENexalin Technology Inc
What's Moving NXL Today?
No stock-specific AI insight has been generated for NXL yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$0.36
Fundamentals
Trading
NXL News
21 articles- Nexalin Technology Announces that the Investigator of Its Brazilian Clinical Trial Received the Young Researcher Award at BRAIN 2026 for Research Evaluating the Company’s Proprietary DIFS™ PlatformYahoo Finance·Jun 23, 2026
- Nexalin Technology (NXL) overhauls bylaws, lowers quorum and adds exclusive forum rulesStock Titan·Jun 17, 2026
- Nexalin Technology Announces Two Clinical Abstracts Accepted for Presentation at the 2026 NYC Neuromodulation Conference Highlighting Preliminary Clinical Results Across Anxiety, Depression, Insomnia and Quality of LifeYahoo Finance·Jun 16, 2026
- Nexalin Technology Reports Compelling Clinical Trial Results in Brazil to Support Product Launch. Trial Demonstrates 77.8% Anxiety Response Rate and Durable Benefits Across Depression, Insomnia and Quality of Life as Company Advances Brazilian Sales Plan.Yahoo Finance·Jun 10, 2026
- EXCLUSIVE: Nexalin Brazil Trial Shows Benefits Across Anxiety, Sleep And Quality Of LifeYahoo Finance·Jun 10, 2026
- Nexalin Technology Announces Issuance of U.S. Patent Covering Dynamic Frequency Stimulation for Anxiety, Depression and Insomniamarkets.businessinsider.com·Jun 4, 2026
- Nexalin Technology Secures Key Neurostimulation Legislative Provision & Commends U.S. House-Passed Report Language Expanding Non-Invasive Deep Brain Neurostimulation Research at the Department of Veterans Affairs for Traumatic Brain InjuryYahoo Finance·May 21, 2026
- Nexalin Acquires AI-Integrated Digital Health Platform Behind HALO™ Clarity and Nexalin NeuroCare™ Ahead of Planned FDA Pivotal TrialYahoo Finance·May 19, 2026
- Nexalin Announces Peer-Reviewed Publication with Neuroimaging Data in Psychotherapy and Psychosomatics Highlighting Brain-Network Effects and Clinical Improvement in Chronic InsomniaYahoo Finance·Apr 28, 2026
- Nexalin Technology Advances Pivotal Clinical Trial of HALO™ Clarity Toward Q2 2026 EnrollmentYahoo Finance·Apr 22, 2026
- RedChip's Biotech Investor Conference Replays Now AvailableYahoo Finance·Apr 20, 2026
- April 2026 Global's Top Undervalued Small Caps With Insider ActionYahoo Finance·Apr 17, 2026
- ASX Stocks That May Be Trading Below Their Estimated ValueYahoo Finance·Apr 16, 2026
- Nexalin Advances FDA Alzheimer’s Strategy Following Landmark Leadership Meetings in the U.S. and ChinaYahoo Finance·Apr 15, 2026
- Join Nexalin’s Exclusive Live Investor Webinar and Q&A Session on April 21Yahoo Finance·Apr 14, 2026
- Nexalin Announces Peer-Reviewed Study Showing the Company’s DIFS™ Technology Reduced Self-Injury and Depression Symptoms in Female AdolescentsGlobeNewswire Inc.·Apr 9, 2026
- RedChip Showcases Public Companies Driving Biotech Innovation at April 16 Virtual Investor ConferenceYahoo Finance·Apr 2, 2026
- Three High Growth Tech Stocks in AustraliaYahoo Finance·Mar 29, 2026
- Nexalin Announces Pivotal HALO™ Clarity Trial to Support Planned De Novo FDA Submission Targeting Multi-Billion-Dollar Insomnia MarketYahoo Finance·Feb 24, 2026
- Nexalin Participates in and Commends Recent Congressional Momentum Supporting Deep Brain Neurostimulation Research for Veterans and Neurological DisordersYahoo Finance·Feb 23, 2026
- Nexalin Technology and First Phosphate Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TVYahoo Finance·Feb 13, 2026
All 21 articles loaded
Price Data
52-Week Range
$0.36
Fundamentals
Trading
About Nexalin Technology Inc
Nexalin Technology Inc. is an innovative leader in the medical technology sector, focused on revolutionizing the treatment landscape for neurological and psychiatric disorders through its proprietary transcranial electrical stimulation devices. The company’s non-invasive therapies address critical mental health challenges, including anxiety, depression, and substance addiction, underscoring its dedication to enhancing patient outcomes and advancing mental health solutions. With a solid foundation in research and a strategic emphasis on leveraging burgeoning demand for advanced healthcare innovations, Nexalin is poised for significant growth in the evolving digital health marketplace, making it an attractive prospect for institutional investors.